Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Oncoimmunology|June 15, 2018
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasisHeidi Harjunpää, Stephen J Blake, Elizabeth Ahern, et al.
Cancer Cell|March 20, 2018
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma MicroenvironmentKyohei Nakamura, Sahar Kassem, Alice Cleynen, et al.
The Journal of Clinical Investigation|April 21, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Blood|July 11, 2018
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myelomaCamille Guillerey, Heidi Harjunpää, Nadège Carrié, et al.
JCI Insight|June 14, 2019
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma modelCamille Guillerey, Kyohei Nakamura, Andrea C Pichler, et al.
The Journal of Clinical Investigation|October 10, 2018
Bone marrow transplantation generates T cell-dependent control of myeloma in miceSlavica Vuckovic, Simone A Minnie, David Smith, et al.
Immunity|July 1, 2023
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiationAndrea C Pichler, Nadège Carrié, Marine Cuisinier, et al.
Clinical & Translational Immunology|February 28, 2018
Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infectionSusanna S Ng, Fernando Souza-Fonseca-Guimaraes, Fabian de Labastida Rivera, et al.
Immunity|October 14, 2020
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer ImmunotherapyMarianne Weulersse, Assia Asrir, Andrea C Pichler, et al.
Pageof 3